Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
A clinical trial update evaluating whether reducing chemotherapy doses affects survival in older patients with non-small cell lung cancer la…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) [Phase 2]
This clinical trial update describes a Phase 2 window-of-opportunity study evaluating durvalumab (MEDI4736) in operable non-small cell lung …
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
A prospective observational Phase II trial is profiling immune responses in stage III non-small cell lung cancer patients treated with concu…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer [Phase 3]
Phase 3 clinical trial update evaluating durvalumab with oleclumab or durvalumab with monalizumab after concurrent chemoradiation in stage I…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Tulmimetostat, an EZH2 inhibitor, in combination with a PD-1 blockade for advanced non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib [Phase 2]
A Phase 2 trial is evaluating lazertinib in combination with pemetrexed and carboplatin for EGFR-sensitizing mutation-positive recurrent or …
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) [Phase 2]
Phase 2 clinical trial update for SKB264 (MK-2870) in advanced or metastatic non-small cell lung cancer. The study is currently active but n…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This update describes a clinical trial evaluating first-line ipilimumab plus nivolumab in locally advanced or metastatic non-small cell lung…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC [Phase 2]
A Phase 2 clinical trial is evaluating an immunochemotherapy approach with surgery or chemoradiation followed by durvalumab for stage IIIA/B…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm [Phase 2]
Clinical trial update indicating the Phase 2 study of adjuvant osimertinib in non-small cell lung cancer with uncommon EGFR mutations is cur…
-
EMA approval · 2026-01-26EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited
EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous c…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. [Phase 1]
A Phase 1 trial evaluates BI 754111 alone and in combination with BI 754091 in patients with advanced cancer, testing multiple doses to iden…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. [Phase 2, Phase 3]
Clinical trial update on the safety and efficacy of EIK1001 in combination with pembrolizumab and chemotherapy for Stage 4 non-small cell lu…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC [NA]
A clinical trial update describing efforts to optimize endobronchial ultrasound sampling for detecting molecular markers in non-small cell l…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
A clinical trial update indicates recruitment is ongoing for a study of large granular lymphocytes in metastatic non-small cell lung cancer …
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study [Phase 2]
Phase 2 trial evaluating furmonertinib at 160 mg versus 80 mg with chemotherapy in EGFR-mutated non-small cell lung cancer with brain metast…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [Phase 2]
This clinical trial update reports a Phase 2 study of LY2875358 in participants with non-small cell lung cancer harboring activating EGFR mu…
-
CLINICAL_TRIALS other · 2026-01-26Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer [Phase 1]
Phase 1 clinical trial entry for abemaciclib (Verzenio) in non-small cell lung cancer and breast cancer. The study status is active but not …
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC [Phase 2]
A Phase 2 clinical trial update evaluating tiragolumab in combination with atezolizumab and bevacizumab for previously treated advanced non-…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) [Phase 2, Phase 3]
An ongoing Phase 2/3 trial in an expanded Lung-MAP study evaluating cemiplimab added to standard treatment for advanced non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: First in Human Study of SIM0610 in Solid Tumors [Phase 1]
A first-in-human Phase 1 study of SIM0610 in solid tumors is underway, evaluating safety and dosing across multiple indications including No…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) [Phase 2]
SWOG's expanded Lung-MAP trial is evaluating a targeted therapy for advanced non-small cell lung cancer with MET exon 14 skipping mutations;…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) [Phase 3]
Phase 3 trial DUBLIN-4 compares docetaxel plus plinabulin vs docetaxel plus placebo in advanced/metastatic non-squamous non-small cell lung …